Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/177408
Title: | Incidence and predictive biomarkers of Clostridioides difficile infection in hospitalized patients receiving broad-spectrum antibiotics |
Author: | van Werkhoven, Cornelis H. Ducher, Annie Berkell, Matilda Mysara, Mohamed Lammens, Christine Torre Cisneros, Julian Rodríguez Baño, Jesús Herghera, Delia Cornely, Oliver A. Biehl, Lena M. Bernard, Louis Domínguez Luzón, Ma. Ángeles (María Ángeles) Maraki, Sofia Barraud, Olivier Nica, Maria Jazmati, Nathalie Sablier, Frederique Gunzburg, Jean de Mentré, France Malhotra-Kumar, Surbhi Bonten, Marc J. M. Vehreschild, Maria J. G. T. Pujol Rojo, Miquel ANTICIPATE Study Group |
Keywords: | Malalties bacterianes Antibiòtics Microbiota Bacterial diseases Antibiotics Microbiota |
Issue Date: | 2021 |
Publisher: | Nature Publishing Group |
Abstract: | Trial enrichment using gut microbiota derived biomarkers by high-risk individuals can improve the feasibility of randomized controlled trials for prevention of Clostridioides difficile infection (CDI). Here, we report in a prospective observational cohort study the incidence of CDI and assess potential clinical characteristics and biomarkers to predict CDI in 1,007 patients ≥ 50 years receiving newly initiated antibiotic treatment with penicillins plus a beta- lactamase inhibitor, 3rd/4th generation cephalosporins, carbapenems, fluoroquinolones or clindamycin from 34 European hospitals. The estimated 90-day cumulative incidences of a first CDI episode is 1.9% (95% CI 1.1-3.0). Carbapenem treatment (Hazard Ratio (95% CI): 5.3 (1.7-16.6)), toxigenic C. difficile rectal carriage (10.3 (3.2-33.1)), high intestinal abundance of Enterococcus spp. relative to Ruminococcus spp. (5.4 (2.1-18.7)), and low Shannon alpha diversity index as determined by 16 S rRNA gene profiling (9.7 (3.2-29.7)), but not nor- malized urinary 3-indoxyl sulfate levels, predicts an increased CDI risk. |
Note: | Reproducció del document publicat a: https://doi.org/10.1038/s41467-021-22269-y |
It is part of: | Nature Communications, 2021, vol. 12 |
URI: | http://hdl.handle.net/2445/177408 |
Related resource: | https://doi.org/10.1038/s41467-021-22269-y |
ISSN: | 2041-1723 |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) Articles publicats en revistes (Patologia i Terapèutica Experimental) Publicacions de projectes de recerca finançats per la UE |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
711934.pdf | 734.65 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License